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A B S T R A C T
Background: Tryptophan breakdown is an important mechanism in several diseases e.g. inﬂammation and stress-
induced inﬂammation have been associated with the development of depression via enhanced tryptophan
breakdown. Depression is a major public health problem which commonly starts during adolescence, thus
identifying underlying mechanisms during early life is crucial in prevention. The aim of this work was to verify
whether independent and interacting associations of psychosocial stress and inﬂammation on tryptophan
breakdown already exist in children and adolescents as a vulnerable age group.
Methods: Two cross-sectional population-based samples of children/adolescents (8–18 y) were available: 315
from the European HELENA study and 164 from the Belgian ChiBS study. In fasting serum samples, tryptophan,
kynurenine, kynurenic acid, C-reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-α, inter-
feron (IFN)-ɣ, soluble vascular adhesion molecule 1 (sVCAM1) and soluble intercellular adhesion molecule 1
(sICAM1) were measured. Psychological stress was measured by stress reports (subjective) and cortisol (objec-
tive – awakening salivary cortisol or hair cortisol). Linear regressions with stress or inﬂammation as predictor
were adjusted for age, sex, body mass index, puberty, socio-economic status and country.
Results: In both cohorts, inﬂammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated
with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0.145–0.429). Psychological
stress was only associated with tryptophan breakdown in the presence of higher inﬂammatory levels (TNF-α in
both populations).
Conclusions: Inﬂammatory levels were replicable key in enhancing tryptophan breakdown along the kynurenine
pathway, even at young age and in a non-clinical sample. The stress-inﬂammation interaction indicated that only
the stress exposures inducing higher inﬂammatory levels (or in an already existing inﬂammatory status) were
associated with more tryptophan breakdown. This data further contributes to our understanding of pathways to
disease development, and may help identifying those more likely to develop stress or inﬂammation-related
illnesses.
1. Introduction
The tryptophan-kynurenine pathway which catabolizes 95% of
tryptophan, has been linked to several diseases like psychological dis-
orders, impaired cognition and cardiometabolic diseases (O’Farrell and
Harkin, 2017; Oxenkrug, 2010a). In this tryptophan-to-kynurenine
breakdown (Fig. 1), two enzymes have a leading role: indoleamine 2,3-
dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO) (Oxenkrug,
2010b). IDO1 activity is mainly induced by pro-inﬂammatory mole-
cules such as interferon (IFN)-ɣ, IFN-α and tumor necrosis factor (TNF)-
α as IDO1 is widely expressed on immune cells like dendritic cells,
macrophages, microglia and eosinophils (Takikawa et al., 1999). TDO is
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involved in the negative feedback i.e. high tryptophan will stimulate
tryptophan breakdown via TDO activation, but also stress, mainly via
the stress hormone cortisol, can induce TDO activity (Gibney et al.,
2014). The IDO1 and TDO stimulated conversion of tryptophan to ky-
nurenine will also lead to diminished serotonin production as trypto-
phan is a precursor of serotonin (Oxenkrug, 2010b). The resulting ky-
nurenine can largely be metabolised via two pathways (Oxenkrug,
2010b; Schwarcz et al., 2012) (Fig. 1): (1) via the formation of ky-
nurenic acid as a neuroprotective and anti-inﬂammatory metabolite or
(2) via the predominantly neurotoxic and pro-inﬂammatory quinolinic
acid branch because of N-methyl-D-aspartate receptor stimulation, lipid
peroxidation and disruption of the blood-brain barrier (although also
functional metabolites like NAD arise in this branch). Consequently, the
kynurenine/tryptophan ratio reﬂects the ﬁrst step of tryptophan
breakdown by TDO or IDO, while the kynurenic acid/kynurenine ratio
can reﬂect a next step away from the pro-inﬂammatory tryptophan
metabolites.
It has now become apparent that this tryptophan-to-kynurenine
breakdown contributes to the development of age-associated neu-
roendocrine disorders (hypertension, dyslipidaemia, type 2 diabetes,
obesity, vascular cognitive impairment and some hormone-related
cancers) and mood disorders (O’Farrell and Harkin, 2017; Oxenkrug,
2010a). Partially this is because of apoptotic, neurotoxic, and pro-oxi-
dative eﬀects of certain tryptophan metabolites like quinolinic acid;
partially this is because of diminished serotonin production which is
linked to mood, sleep, sexual behaviour, cognition and appetite
(Hulsken et al., 2013; O’Farrell and Harkin, 2017; Oxenkrug, 2010a).
Because of IDO and TDO activity, inﬂammation and stress may be
two pathological situations aﬀecting tryptophan breakdown and can
converge to have further health deteriorating results via this mutual
pathophysiological process, especially when an optimal supply of
tryptophan and its metabolites to the central nervous system is desir-
able. Of particular interest is the increasing amount of evidence that
inﬂammation and chronic stress might stimulate each other via inter-
action between cytokines and cortisol (Hansel et al., 2010; Leonard,
2005). Nevertheless, only a few studies exist on the role of inﬂamma-
tion (cytokines and related molecules like acute phase proteins and cell-
adhesion molecules) and stress in the tryptophan breakdown using an
overall population sample (Deac et al., 2016; Elovainio et al., 2012;
Pertovaara et al., 2007) and none in children. Research has often fo-
cused on patients with depression showing higher tryptophan break-
down (Maes et al., 1993; Myint et al., 2013), but not in everyone
(Gabbay et al., 2010). Concerning inﬂammation, IFN-ɣ is known as the
strongest inducer of IDO1, although this association is not always evi-
dent in healthy populations (Deac et al., 2016; Fitzgerald et al., 2008).
Thus, a better understanding of the role of tryptophan breakdown fol-
lowing psychosocial stress and inﬂammation during vulnerable periods
like childhood and adolescence, and hence early in the disease process,
is necessary.
The goal of the current paper is to examine whether the association
of inﬂammation and stress with tryptophan metabolites could be al-
ready observed in children and adolescents. This is important as tryp-
tophan breakdown could then potentially be used as early target for
prevention. To allow replication, the independent and interacting as-
sociations of psychosocial stress (subjectively and objectively mea-
sured) and inﬂammation (six markers) on enhanced tryptophan
breakdown was tested in two population samples of children and
adolescents.
2. Methods
2.1. Study samples
Two population samples of children/adolescents have been used.
The HELENA-Cross Sectional Study was conducted in 3528 adoles-
cents aged 12.5–17.5 from 10 European cities from 2006 to 2007.
Details on sampling procedures and study design of the HELENA study
have been reported elsewhere (Moreno et al., 2008). For this paper,
speciﬁc inclusion criteria were the availability of serum (and thus
tryptophan and inﬂammation data) and the stress questionnaire (which
was an optional module) and the absence of an acute infection
(CRP > 10mg/l) as was the case in 315 adolescents. Included parti-
cipants seemed to have a lower BMI than those with missing data (z-
score 0.2 vs 0.5), but did not diﬀer in sex or age. Only in a subsample
(n= 161, from the same six countries), salivary cortisol was available;
this sample did not diﬀer in BMI or sex but was somewhat younger
(mean age 14.3 vs 14.8 y, but same age range) than the other 155 in-
cluded participants.
Fig. 1. The tryptophan breakdown pathway.
TDO=tryptophan 2,3-dioxygenase, IDO
= indoleamine 2,3-dioxygenase. Metabolites in
the blue boxes were measured in the current
study. Interesting, some metabolites of kynur-
enine like kynurenic acid are anti-inﬂammatory
and neuroprotective, while others like quinolinic
acid are pro-inﬂammatory and neurotoxic.
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For the longitudinal ChiBS study, participants were Dutch-speaking
Belgian children (Michels et al., 2012b); 242 children aged 8–16 were
included in the March-May 2015 period (as a two-hour appointment at
the local sports park). Fasting serum levels were analysed on a detailed
set of inﬂammatory and tryptophan metabolism parameters. In addi-
tion, stress was measured by hair cortisol analysis and questionnaires
(stressors and emotions). None of children had a reported diagnosis of
Cushing/Addison disease, auto-immune disease, acute infection or
clinical depression. Nobody took oral anti-inﬂammatory drugs or se-
lective serotonin reuptake inhibitors. One child using oral corticoster-
oids, two children with a CRP > 10mg/l (indicative for acute infec-
tion) and three children with fever in the last 3 days were excluded.
This paper included only 164 participants with complete info on
questionnaire data, inﬂammatory markers and tryptophan-to-kynur-
enine breakdown. Included participants did not diﬀer in age, BMI or sex
compared to excluded ones. Only in a subsample (n=81), valid hair
cortisol data was available; this sample did not diﬀer in age or BMI but
included more girls (59% versus 21%) due to often too short hair in
boys.
The studies were conducted according to the guidelines laid down in
the Declaration of Helsinki and the project protocol was approved by
the Ethics Committee of the Ghent University Hospital (EC/2006/086,
EC/2009/688). A written informed consent was obtained from the
parents and a verbal assent from the children/adolescents.
2.2. Stress measures
Stress arises when the demands of a situation exceed an individual’s
ability to cope and resolve the problem, resulting in emotional and
behavioral disturbances (McCance et al., 2006). Via questionnaires,
negative events (environmental level) and/or emotions (psychological
level) are aspects that reﬂect stress exposure. On biological level, cor-
tisol is the most often used biomarker and can be measured in several
matrices like blood, saliva and hair (Vanaelst et al., 2012a). In HELENA,
a questionnaire on negative events and salivary cortisol were used. In
ChiBS, a questionnaire reﬂecting negative events, a questionnaire re-
ﬂecting negative emotions and cortisol in hair were used.
2.2.1. Negative events in HELENA (n= 315)
Adolescents completed the 56-item Adolescent Stress Questionnaire
(De Vriendt et al., 2011b) divided in 10 component scales: stress of
home life, school performance, school attendance, romantic relation-
ships, peer pressure, teacher interaction, future uncertainty, school/
leisure conﬂict, ﬁnancial pressure and emerging adult responsibility.
Respondents were asked to indicate on a 5-point Likert scale (1= “not
at all stressful (or is irrelevant to me)”, 2= “a little stressful”,
3= “moderately stressful”, 4= “quite stressful”, 5= “very stressful”)
how stressful these items had been to them during the past year. A
stress summary score was obtained by adding the individual scores of
all 56 items.
2.2.2. Salivary cortisol in HELENA (n=161)
In HELENA, baseline (without stimulation) wake-up salivary free
cortisol was collected immediately after awakening. To account for
intra-individual variability, awakening samples from seven consecutive
days were collected (the same week as all other measures) and the
mean was used. Participants got an oral explanation on the sampling
and a detailed instruction sheet was provided. Saliva was collected with
Salivettes® (Sarstedt, Germany), allowing stable samples at room tem-
perature for a minimum of one week. The Salivettes® were centrifuged
at 2000g for 10min, and the ﬁltrates were stored at −20 °C. Salivary
cortisol was measured using a modiﬁcation of an unextracted radio-
immunoassay method (Diasorin) for serum cortisol (routine lab Ghent
University Hospital). Brieﬂy, 200 μl saliva was pipetted into the coated
tube and incubated with 125I cortisol for 45min at 37 °C. The modiﬁed
cortisol assay had a 0.5–30 μg/l measuring range. Only those
adolescents who had at least three saliva samples collected between 6
a.m. and 8 a.m. were included.
2.2.3. Negative events in ChiBS (n=164)
The Coddington Life Events Scale for Children (CLES-C) is a vali-
dated and well-established 36-item questionnaire (test-retest r= 0.69,
parent-child agreement ICC=0.45) (Coddington, 1999). By child self-
report, it assesses the prevalence, frequency and timing of stressful life
events relevant for this age group during the last year. By measuring
signiﬁcant life events in terms of Life Change Units depending on
timing, frequency and severity, the questionnaire can provide insight
into recent events that may aﬀect the child’s health.
2.2.4. Negative emotions score in ChiBS (n= 164)
Since a young childhood sample is concerned, a short and easy-to-
understand questionnaire on emotions was chosen. Feelings of anger,
anxiety and sadness could be rated on a 0 (not at all) to 10 (very strong)
Likert-scale. The negative emotions score (sum of three negative emo-
tions) showed a Spearman correlation of r= 0.48 (p < 0.001) with the
negative aﬀect score of the validated PANAS-C questionnaire (Laurent
et al., 1999) (tested in a subsample i.e. participant in our 2013 study
wave that were at least 9 y old).
2.2.5. Hair cortisol in ChiBS (n=81)
Hair cortisol has recently been established as a reliable correlate of
chronic stress exposure (Wester and van Rossum, 2015). Only the most
proximal 3 cm of the hair strands from the vertex posterior were ana-
lysed. Since hair grows approximately 1 cm each month, this 3 cm re-
ﬂects the exposure during the last 3 months. Extraction and liquid
chromatography coupled with tandem mass spectrometry was per-
formed at the Laboratory for Hormonology, Ghent University Hospital.
To start, 15mg of hair was milled in a Retch Ballmill MM200. After
addition of 2ml Sorenson buﬀer and 20 μl of Cortisol-d4 internal
standard, hair samples were incubated overnight at 42 °C. Then, 1.8ml
of buﬀer 100 μl NaOH (1M) was added and mixed. After extraction
with 2.5 ml diethylether and mixing for 3min, samples were frozen and
decanted with subsequent drying of the collected supernatant. The
dried supernatant was then reconstituted in a ﬁnal solution of 125 μl
methanol of which 100 μl was injected for liquid chromatography.
Cortisol was acquired from Sigma Aldrich (Saint Louis, USA), d4-cor-
tisol from CDN Isotopes (Quebec, Canada). All standards and internal
standards were dissolved in methanol. An AB Sciex 5500 triple-quad-
rupole mass spectrometer (AB Sciex; Toronto, Canada) was used, cou-
pled with an APCI probe on the Turbo-V source. The liquid chromato-
graphy system consisted of a Shimadzu system using a C8 security
guard column (5 um,4× 2mm) and a C8 Luna analytical column (3um,
50× 3mm) (Phenomenex; Torrance, USA). Measurements were per-
formed by the tandem mass spectrometer running in multiple reaction
monitoring mode by using transitions m/z 363/121/97 for cortisol and
d4-cortisol on m/z 367/121/97. A declustering potential of 100 V and a
collision energy 32 eV was used for all the analytes. Data processing
was performed through MultiQuant version 2.0.2. Inter-assay CV for
cortisol was 10.8% with a limit-of-quantiﬁcation of 1.6 pg/mg hair.
2.3. Biomarkers of inﬂammation
Six inﬂammatory parameters were analysed in fasting serum after
storage at −80 °C: Acute-phase protein C-reactive protein (CRP), IL-6,
TNF-α, IFN-ɣ soluble vascular adhesion molecule 1 (sVCAM1) and so-
luble intercellular adhesion molecule 1 (sICAM1). Participants with
fever during the last 24 h were excluded and nobody used nonsteroidal
anti-inﬂammatory drugs. For ChiBS, samples were analysed in dupli-
cate by enzyme-linked immunosorbent assay (ELISA) using electro-
chemiluminescent multiplex kits (VPlex by Meso Scale Discovery,
Maryland, USA) with a Sector 2400 analyser at the APC microbiome
institute at the University College Cork in Ireland (intra-assay CV 2–4%,
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inter-assay CV 5–11%). For HELENA, CRP was measured in serum by
immunoturbidimetry (AU2700 biochemistry analyzer; Olympus,
Rungis, France) while IL-6, TNF-α, IFN-ɣ, sVCAM1 and sICAM1 were
determined using the High Sensitivity Human Cytokine MILLIPLEXTM
MAP kit (Millipore Corp., Billerica, MA, USA) and collected by ﬂow
cytometry (Luminex–100 v.2.3, Luminex Corporation, Austin, TX,
USA). Including or excluding samples with values below the detection
limit (< 5% of samples) did not change the results.
2.4. Tryptophan breakdown
For both ChiBS and HELENA serum samples, tryptophan, kynur-
enine and kynurenic acid were determined at the APC microbiome in-
stitute at University College Cork in Ireland. Brieﬂy, serum samples
were spiked with internal standard (3-Nitro-L-tyrosine) prior to being
deproteinised by the addition of 20 μl of 4M perchloric acid to 200 μl of
sample. Samples were centrifuged at 21,000g on a Hettich Mikro 22R
centrifuge (AGB, Dublin, Ireland) for 20min at 4 °C and 100 μl of su-
pernatant transferred to a HPLC vial for analysis on the HPLC system
(UV and FLD detection). All samples were injected onto a reversed
phase Luna 3 μm C18 (2) 150× 2mm column (Phenomenex), which
was protected by KrudKatcher disposable pre-column ﬁlters
(Phenomenex) and SecurityGuard cartridges (Phenomenex). The mo-
bile phase consisted of 50mM acetic acid and 100mM zinc acetate with
3% (v/v) acetonitrile and was ﬁltered through Millipore 0.45-μm HV
Durapore membrane ﬁlters (AGB) and vacuum degassed prior to use.
Compounds were eluted isocritically over a 30-min runtime at a ﬂow
rate of 0.3ml/min after a 20-μl injection. The column was maintained
at a temperature of 30 °C, and samples/standards were kept at 8 °C in
the cooled autoinjector prior to injection. The ﬂuorescent detector was
set at an excitation wavelength of 254 nm and an emission wavelength
of 404 nm. The UV detector was set to 330 nm. L-tryptophan, kynur-
enine and kynurenic acid were identiﬁed by their characteristic reten-
tion times as determined by standard injections which were run at
regular intervals during the sample analysis. Internal standard peak
height ratios were measured and compared with standard injections,
and results were expressed as nanogram per millilitre of serum. Apart
from the three single metabolites (blue boxes in Fig. 1), we used the
kynurenine/tryptophan ratio as marker of enhanced tryptophan
breakdown by TDO or IDO and the kynurenic acid/kynurenine ratio as
marker of the next breakdown step away from the predominantly pro-
inﬂammatory and neurotoxic quinolinic acid pathway.
2.5. Possible confounders
Pubertal status (stages I–V) was assessed by a doctor using the
Tanner and Whitehouse criteria (Tanner and Whitehouse, 1976). Body
mass index (BMI) was calculated by dividing measured weight by
height squared (kg/m2) and the BMI z-score was calculated (Cole et al.,
2000) while overweight was classiﬁed following the International
Obesity Task Force. To represent socio-economic status, parental edu-
cation level was assessed by questionnaire according to the Interna-
tional Standard Classiﬁcation of Education. Diet was not included in the
regression since neither tryptophan intake nor protein intake was re-
lated to any of the tryptophan serum variables.
2.6. Statistical analyses
Statistical analyses were performed using SPSS 22 and all p-va-
lues < 0.05 were considered signiﬁcant. Spearman correlations were
performed for continuous variables. Linear regression analyses tested the
association of stress and inﬂammation with tryptophan status (tryptophan,
kynurenine, kynurenic acid, kynurenine/tryptophan and kynurenic acid/
kynurenine) after adjustment for age, sex, BMI, puberty, socio-economic
status (and in the HELENA population also country). First, a multivariate
linear regression with all six inﬂammatory parameters together was run to
see the overall inﬂammation association (without multiple testing).
Second, separate models for stress and inﬂammation as predictor of in-
terest were tested. Third, inﬂammation and stress were put together in one
model to detect independent associations. Standardized regression coeﬃ-
cients were reported. When the regression residuals were not normally
distributed, outcome variables were transformed by calculating the loga-
rithm, which was the case for kynurenic acid and the kynurenic acid/
kynurenine ratio. No signiﬁcant sex*stress or sex*inﬂammation interac-
tion was found.
Finally, the moderation of inﬂammation in the stress-tryptophan
relation was tested. This was only performed for the theoretically most
relevant tryptophan parameter i.e. the kynurenine/tryptophan ratio by
adding the interaction term “stress*inﬂammation” as predictor of ky-
nurenine/tryptophan, after centring the predictors. In the case of a
signiﬁcant interaction, the stress – kynurenine/tryptophan relation was
tested for 3 representative groups: those at the mean, at 1 SD below the
mean and 1 SD above the mean of the inﬂammatory parameter.
Sensitivity analysis: Running all analyses on the subsample that had
also cortisol values (n= 81 for ChiBS, n= 161 for HELENA) did not
change the main results, there was only one signiﬁcant ﬁnding in the
HELENA sample that became borderline signiﬁcant (p=0.052,
beta= 0.140 for the association between sICAM1 and kynurenine/
tryptophan).
3. Results
3.1. Descriptive data
Descriptive data for both population samples is given in Table 1. All
children in the ChiBS sample came from Belgium; the age ranged from 8
to 16 years; whereas HELENA is a European representative sample with
children coming from: 28.8% Belgium, 24.9% Sweden, 17.2% Spain,
13.1% Hungary, 9.5% Austria, 6.5% Greece; the age ranged from 12.5
to 17.5y. The two population samples diﬀered in almost all parameters
of interest and were thus rather complementary: the ChiBS population
had a younger age group, higher proportion of females, higher socio-
economic status, but lower adiposity, kynurenine/tryptophan and in-
ﬂammatory levels with the exception of IFN-ɣ, sICAM1 and TNF-α. OF
course, it should be considered that age might be a reason for diﬀerent
serum levels. A correlation matrix can be found in Supplementary
material.
3.2. Association of inﬂammation with tryptophan breakdown
A multivariate linear regression showed an overall signiﬁcant as-
sociation between inﬂammation parameters and kynurenine/trypto-
phan ratio (ChiBS: p < 0.001, partial eta squared=0.228; HELENA:
p=0.056, partial eta squared= 0.110). Table 2 presents the linear
regression results for inﬂammation as predictor of tryptophan pathway
parameters in both studies. In both samples, higher CRP, sVCAM1 and
sICAM1 were positively associated with a higher kynurenine/trypto-
phan ratio. We also observed positive associations of IFN-ɣ and TNF-α
with this kynurenine/tryptophan ratio in the ChiBS and HELENA
sample, respectively. In line with this ratio, higher kynurenine (with
CRP and IFN-ɣ) and lower tryptophan levels (with CRP and sVCAM1)
were related to inﬂammation in ChiBS. Kynurenic acid was not related
to the inﬂammatory parameters. After Bonferroni correction (p= 0.004
i.e. 0.05/12 since six inﬂammatory parameters were tested in two po-
pulations), all 4 ﬁndings related to kynurenine/tryptophan in the ChiBS
sample (CRP, IFN-ɣ, sVCAM1, sICAM1) remained signiﬁcant. Supple-
mentary Table 2 represents the same results but with inﬂammatory
parameters scaled per interquartile range (IQR) to get an idea of eﬀect
sizes. The maximum eﬀect size on kynurenine/tryptophan was by CRP
in the ChiBS population: one IQR change in CRP was associated with
0.006 units increase in kynurenine/tryptophan, which is half of an IQR
increase (see Table 1), thus a rather large eﬀect size.
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3.3. The role of stress in tryptophan breakdown
Since we hypothesize that inﬂammation observed in this group
could be due to stress, we added stress variables to the above mentioned
regression, but no changes in signiﬁcant ﬁndings were detected (data
not shown). Indeed, Table 3 shows that none of the stress parameters
was signiﬁcantly associated with the tryptophan pathway parameters.
In Supplementary Fig. 1, scatterplots clearly show that stress is only
related to some inﬂammatory markers (sVCAM1 and sICAM1) and only
in the ChiBS population. Finally, when checking their interactive eﬀect,
signiﬁcant moderation between reported stress (events or emotions)
and inﬂammation was found in their association with the kynurenine/
tryptophan ratio. Replicable in both populations (ChiBS and HELENA),
a positive association between stress reports and kynurenine/trypto-
phan was found only in case of high TNF-α levels (Fig. 2). For IFN-ɣ
(p < 0.001; R2change= 0.09), sVCAM1 (p=0.007;
R2change=0.04) or sICAM (p < 0.001, R2change= 0.06), this was
only the case in the ChiBS population.
4. Discussion
Replicable in two independent population samples of children/
adolescents, inﬂammation (high CRP, sVCAM1 and sICAM1) was con-
ﬁrmed as a key positive predictor of the kynurenine/tryptophan ratio
(Table 2). The resulting lowered tryptophan during this vulnerable age-
period might be a pathway to higher morbidity (e.g. psychological
disorders, impaired cognition and cardiometabolic disorders) including
ones that typically develop during adolescence such as major depressive
disorders. Although stress reports and cortisol levels were not asso-
ciated with tryptophan metabolism (Table 3), signiﬁcant stress-
Table 1
Descriptive data of the two population samples.
HELENA
(n=315)
ChiBS
(n= 164)
p-value: HELENA vs ChiBS
Median [p25; p75]
or %
median [p25; p75]
or %
sex (% male) 42.7% 54.8% <0.001
age (years) 14.5 [13.6; 15.3] 12.6 [11.8.13.8] < 0.001
BMI (z-score) 0.2 [−0.5; 0.9] −0.4 [−0.9; 0.2] < 0.001
overweight (%) 14.6% 3.6% <0.001
SES (% high) 61.7% 83.1% <0.001
puberty (% pubertal) 94.6% 88.2% 0.030
serum values
L-Tryptophan (ng/ml) 11,555 [10,185; 13,257] 11,913 [10,620; 13,640] 0.291
L-Kynurenine (ng/ml) 573 [485; 695] 677 [566; 772] < 0.001
kynurenine/tryptophan 0.049 [0.043; 0.056] 0.056 [0.051; 0.062] < 0.001
kynurenic acid (ng/ml) 3.61 [1.77; 4.87] 3.07 [0; 5.56] 0.129
kynurenic acid/kynurenine 0.006 [0.003; 0.009] 0.004 [0; 0.009] 0.010
CRP (mg/l) 0.556 [0.221; 1.281] 0.267 [0.108; 0.833] < 0.001
IL-6 (pg/ml) 10.02 [4.44; 25.56] 1.07 [0.64; 1.87] < 0.001
TNF-α (pg/ml) 5.74 [4.02; 8.11] 5.87 [4.50; 7.47] 0.059
IFN-ɣ (pg/ml) 0.90 [0.12; 6.97] 4.32 [2.5; 6.7] < 0.001
sVCAM1 (mg/l) 1.196 [0.972; 1.513] 0.657 [0.579; 0.787] < 0.001
sICAM1 (mg/l) 0.122 [0.098; 0.161] 0.498 [0.415; 0.571] < 0.001
stress variables
Cortisol: saliva (HELENA, n= 161) or hair (ChiBS, n=81)) 23.06 nmol/l
[18.81; 27.67]
3.77 pg/mg
[2.78; 5.18]
events: ASQ (HELENA) or CLES (ChiBS) 123 [87; 157] 60 [17; 122]
negative emotions (0–30) / 7 [5; 10]
BMI=body mass index; SES= socio-economic status by parental education; CRP=C-reactive protein; IL-6= interleukin 6; TNF-α=tumor necrosis factor alpha;
IFN-ɣ=interferon gamma; sVCAM= soluble vascular cell adhesion molecule; sICAM= soluble intercellular adhesion molecule; ASQ=adult stress questionnaire;
CLES=Coddington Life Events Scale.
Table 2
Linear regression of inﬂammation parameters with tryptophan metabolites as outcome for the ChiBS (n= 164) and HELENA (n=315) population.
tryptophan Kynurenine kynurenine/tryptophan kynurenic acid kynurenic acid/kunyrenine
HELENA ChiBS HELENA ChiBS HELENA ChiBS HELENA ChiBS HELENA ChiBS
CRP beta −0.088 −0.170 0.059 0.226 0.145 0.429 0.117 0.083 −0.056 0.046
P 0.358 0.032 0.481 0.004 0.035 <0.001 0.143 0.292 0.478 0.562
TNF-α beta 0.010 −0.108 0.091 −0.044 0.112 0.089 −0.002 0.040 −0.036 0.054
P 0.859 0.178 0.091 0.586 0.040 0.267 0.971 0.623 0.465 0.504
IL-6 beta −0.001 0.026 −0.001 0.068 −0.006 0.070 0.002 0.009 −0.048 0.009
p 0.999 0.747 0.988 0.404 0.914 0.392 0.699 0.908 0.382 0.909
IFN-ɣ beta 0.021 −0.110 0.063 0.201 0.073 0.390 −0.023 −0.009 −0.031 −0.024
p 0.694 0.173 0.227 0.021 0.177 <0.001 0.646 0.908 0.541 0.764
sICAM1 beta 0.005 −0.117 0.132 0.148 0.169 0.292 0.093 0.123 0.049 0.130
p 0.951 0.157 0.063 0.074 0.021 <0.001 0.177 0.140 0.429 0.117
sVCAM1 beta −0.085 −0.216 0.065 0.143 0.192 0.340 −0.059 −0.022 −0.032 0.045
p 0.295 0.006 0.358 0.070 0.012 <0.001 0.419 0.783 0.621 0.570
CRP=C-reactive protein; IL-6= interleukin 6; TNF-α=tumor necrosis factor alpha; IFN-ɣ= interferon gamma; sVCAM= soluble vascular cell adhesion molecule;
sICAM= soluble intercellular adhesion molecule. Standardized regression coeﬃcients are shown from linear regression adjusted for age, sex, parental education,
BMI, puberty (and for the HELENA population also country). Bold values= p < 0.05.
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inﬂammation interaction was detected (Fig. 2) since stress reports were
associated with higher kynurenine/tryptophan in case of higher in-
ﬂammatory levels (replicable for TNF-α in both samples); reﬂecting a
stress-associated inﬂammation guiding of tryptophan breakdown.
4.1. Association of inﬂammation with tryptophan breakdown
We ﬁrst showed that inﬂammatory parameters were associated with
higher tryptophan breakdown towards kynurenine. A multivariate
linear regression showed an overall signiﬁcant association between
inﬂammatory parameters and kynurenine/tryptophan with moderate
eﬀect size.
In order to better understand mechanisms, we investigated which
particular inﬂammatory parameter induced tryptophan breakdown.
CRP, sICAM1 and sVCAM1 signiﬁcantly increased tryptophan break-
down via IDO1 enzyme activity in both study populations. CRP as
general acute-phase-protein seemed to be the strongest parameter
(beta= 0.429); this has also been observed in Finnish healthy adults
(Pertovaara et al., 2007) but not in Irish healthy adults (Deac et al.,
2016). We were the ﬁrst to show an association of the atherosclerotic
and inﬂammation-related cell-adhesion molecules sICAM1 and
sVCAM1 with tryptophan breakdown. These cell adhesion molecules
had not been tested yet by others in relation to kynurenine/tryptophan,
although increased kynurenine/tryptophan ratio has been associated
with cardiovascular risk (Pertovaara et al., 2007). IFN-ɣ and TNF-α
were also associated with tryptophan breakdown but only in one of our
two study populations. This role of IFN-ɣ and TNF-α is in agreement
with other studies (Deac et al., 2016; Myint et al., 2013; Wolowczuk
et al., 2012), although IFN-ɣ is not related to kynurenine/tryptophan in
all studies (Deac et al., 2016; Fitzgerald et al., 2008).
In our sample, no signiﬁcant associations with kynurenic acid or its
ratio with kynurenine were found. Similar to our study, no association
between these inﬂammatory parameters and kynurenic acid or kynur-
enine/kynurenic acid ratio is present in a sample of healthy adults
(Deac et al., 2016).
4.2. The role of stress in tryptophan breakdown
Next, we hypothesized that the inﬂammation-induction of trypto-
phan breakdown towards kynurenine would be particularly important
in those with higher levels of stress as stress might stimulate TDO
(Salter and Pogson, 1985) via cortisol or inﬂammatory molecules. We
were particularly interested in individuals high in both stress and in-
ﬂammation, since research shows that in patients with chronic stress
(e.g. major depressive disorder) increased tryptophan breakdown oc-
curs in the presence of inﬂammation (Maes et al., 1993; Myint et al.,
2013). To test this hypothesis, we analysed whether stress moderated
the association between inﬂammation and tryptophan metabolites.
Neither subjective stress as measured by questionnaires nor objective
stress as measured by cortisol levels were associated with tryptophan
breakdown alone. However, there was a signiﬁcant interaction between
stress and TNF-α in tryptophan breakdown in both population samples
showing a moderation eﬀect of stress. This moderation might be
translated as: only stress exposures that induce higher inﬂammatory
levels (or in the presence of an already existing inﬂammatory status)
were associated with more tryptophan breakdown. In this perspective,
subjective stress was not related to higher inﬂammatory markers in the
Table 3
Linear regression of psychological stress with tryptophan metabolites as outcome for the ChiBS and HELENA population.
tryptophan kynurenine kynurenine/tryptophan kynurenic acid kynurenic acid/kunyrenine
HELENA
salivary awakening cortisol (n= 161) beta 0.001 0.067 0.092 −0.043 −0.048
p 0.985 0.368 0.218 0.578 0.514
ASQ (n= 315) beta 0.023 −0.023 −0.074 −0.001 0.011
p 0.677 0.661 0.171 0.998 0.845
ChiBS
hair cortisol (n= 81) beta −0.119 −0.139 −0.065 −0.089 0.108
p 0.258 0.176 0.524 0.393 0.308
CLES (n= 164) beta 0.090 −0.016 −0.065 0.078 0.014
p 0.266 0.847 0.422 0.335 0.862
negative emotions score (n= 164) beta −0.113 −0.119 0.009 −0.084 −0.071
p 0.174 0.154 0.910 0.316 0.396
ASQ= adult stress questionnaire; CLES=Coddington Life Events Scale. Standardized regression coeﬃcients are shown from linear regression adjusted for age, sex,
parental education, BMI, puberty (and for the HELENA population also country).
Fig. 2. Stress-inﬂammation interaction replicable in both the ChiBS (n= 166)
and HELENA (n=316) population.
TNF-α= tumor necrosis factor α.
The moderation of inﬂammation in the association between stress and kynur-
enine/tryptophan was tested by adding the interaction term “stress*in-
ﬂammation” as predictor. Only the signiﬁcant interactions are shown. The
stress – kynurenine/tryptophan relation is shown for 3 representative groups:
those at the mean, at 1 SD below the mean and 1 SD above the mean of the
inﬂammatory parameter.
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whole population (no overall signiﬁcant positive correlations between
stress and inﬂammation observed in our population) but only in some
individuals. Reasons for increased stress-induced inﬂammation in some
individuals is unknown but may involve among others the duration/
level of stress e.g. childhood maltreatment and poverty; or individual
vulnerability like genetics and epigenetic changes (Oxenkrug, 2010a;
Slavich and Irwin, 2014). This was not investigated in this study.
To our knowledge, we are the ﬁrst to report on the stress-in-
ﬂammation and tryptophan breakdown association in a population
sample of children/adolescents. Some reports exist on the direct role of
stress: stress induction in mice increases kynurenine/tryptophan ratio
(Fuertig et al., 2016; Kiank et al., 2010; Liu et al., 2015), while de-
pressive symptoms are related to higher kynurenine/tryptophan in one
study (Elovainio et al., 2012) but not in another (Fitzgerald et al.,
2008). Nevertheless, human studies have not yet tested the stress-in-
ﬂammation interaction in tryptophan breakdown. Conﬁrming our
moderation eﬀect, a cross-talk between inﬂammation and tryptophan
breakdown has been demonstrated in animal models with chronic
stress. For example, stress-induced IDO expression in mice can be
blocked by anti-TNF-α treatment (Kiank et al., 2010; Liu et al., 2015).
Theoretically, stress-inﬂammation interaction is suggested by IDO de-
creasing TDO expression (Guillemin et al., 2007) and by mutual cor-
tisol-inﬂammation stimulation (Turck et al., 2005; Zunszain et al.,
2011). Thus, the combination of chronic inﬂammation and stress might
change tryptophan metabolism (Zunszain et al., 2011).
This tryptophan breakdown has many health implications. Through
formation of kynurenine toxic metabolites, tryptophan is broken down
away from the production of the neuroprotective serotonin (Leonard,
2005). In addition, kynurenine shifted towards production of neuro-
toxic metabolites is implicated in neurodegeneration and immune tol-
erance (Guillemin et al., 2007). Together these changes could lead to
brain damage, ﬁnally evolving towards mental health problems in-
cluding depression (Myint et al., 2007; Myint et al., 2012). Therefore, in
children with high levels of stress and inﬂammation, increased tryp-
tophan breakdown towards toxic kynurenine metabolites may be a
pathway by which stress leads to diseases which often start during
adolescence such as major depression. Targeting inﬂammation and/or
tryptophan breakdown in children with high levels of stress may be a
strategy to prevent the development of depression in vulnerable chil-
dren.
4.3. Strengths and limitations
A major advantage with existing literature was the use of two po-
pulation-based samples of children/adolescents (range 8–18 y), al-
lowing replicable testing whether the expected associations occur al-
ready early in life to indicate pathways for prevention. Current
literature is mainly based on animal and clinical samples and popula-
tion results are scarce, especially in such a young group. The children in
these two cohorts had both subjective and objective measures of stress
and inﬂammatory markers measured. The HELENA dataset is trans-
national and therefore results may be more easily and robustly gen-
eralized.
Yet, the current study has its limitations. A major disadvantage was
the cross-sectional design not allowing assumptions about cause-eﬀect
directionality. Indeed, bidirectionality might be possible e.g. higher
IDO-activity can induce depressive symptoms or enhanced stress vul-
nerability (Elovainio et al., 2012; Leonard, 2005). In addition, trypto-
phan depletion has been shown to inﬂuence salivary cortisol levels
(Vielhaber et al., 2005). A second limitation is the diﬀerent metho-
dology to measure stress within the two studies: diﬀerent event ques-
tionnaires were used, the ChiBS study also included an emotion report,
and the two studies used a diﬀerent matrix for cortisol analysis. Of note,
our stress reports have previously been validated against cortisol levels
(Michels et al., 2012a). Herein, salivary cortisol sampling in the HE-
LENA dataset is less sensitive or representative for long-term cortisol
exposure than hair cortisol in the ChiBS dataset, especially since only
the awakening cortisol and not the diurnal patterns were available
(Golden et al., 2011), but hair-saliva inter-correlations have been re-
ported in literature (Vanaelst et al., 2012b). Also, the stress ques-
tionnaire in the HELENA study shows less than optimal repeatability
and criterion validity (De Vriendt et al., 2011a). A third and important
limitation is that only kynurenine and kynurenic acid but no other
metabolites were determined like quinolinic acid to measure health-
deteriorating pathways of tryptophan breakdown or serotonin to mea-
sure the other important tryptophan pathway. This decision was taken
due to additional ﬁnancial costs and due to interpretation uncertainty
of these metabolites’ blood concentration: transport of serotonin and
quinolinic acid through the blood-brain barrier is questionable (Fukui
et al., 1991; Nakatani et al., 2008) and blood serotonin might reﬂect
rather peripheral processes (e.g. serotonin production in the gastro-
intestinal tract). Nevertheless, the kynurenine/tryptophan ratio might
be inﬂuenced by this downstream kynurenine breakdown towards
quinolinic acid, instead of purely reﬂecting IDO1 activity as is hy-
pothesized in this manuscript. Thus further research on these down-
stream metabolites will better frame the health eﬀects.
5. Conclusion
This study demonstrated by replication in two independent popu-
lation samples that already during childhood/adolescence inﬂamma-
tion leads to higher tryptophan breakdown and thus to further mor-
bidity in this vulnerable age-group. Moreover, the signiﬁcant stress-
inﬂammation interaction indicated that only stress exposures inducing
higher inﬂammatory levels (or in the presence of an already existing
inﬂammatory status) were associated with increased tryptophan
breakdown. This might enable the identiﬁcation of an at-risk popula-
tion with higher stress and inﬂammation vulnerability that are then at
risk for health-deteriorating eﬀects of tryptophan breakdown.
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